Biogen Inc. (BIT:1BIIB)
Italy flag Italy · Delayed Price · Currency is EUR
103.40
0.00 (0.00%)
At close: May 9, 2025, 5:30 PM CET

Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of EUR 16.39 billion. The enterprise value is 20.01 billion.

Market Cap 16.39B
Enterprise Value 20.01B

Important Dates

The last earnings date was Thursday, May 1, 2025.

Earnings Date May 1, 2025
Ex-Dividend Date n/a

Share Statistics

Current Share Class 146.53M
Shares Outstanding n/a
Shares Change (YoY) +0.21%
Shares Change (QoQ) +0.34%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 146.16M

Valuation Ratios

The trailing PE ratio is 11.98 and the forward PE ratio is 8.11.

PE Ratio 11.98
Forward PE 8.11
PS Ratio 1.80
PB Ratio 1.04
P/TBV Ratio 19.32
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.95, with an EV/FCF ratio of 8.88.

EV / Earnings 14.62
EV / Sales 2.27
EV / EBITDA 6.95
EV / EBIT 9.38
EV / FCF 8.88

Financial Position

The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.39.

Current Ratio 1.44
Quick Ratio 0.87
Debt / Equity 0.39
Debt / EBITDA 2.07
Debt / FCF 2.72
Interest Coverage 9.84

Financial Efficiency

Return on equity (ROE) is 9.19% and return on invested capital (ROIC) is 6.48%.

Return on Equity (ROE) 9.19%
Return on Assets (ROA) 5.43%
Return on Invested Capital (ROIC) 6.48%
Return on Capital Employed (ROCE) 10.43%
Revenue Per Employee 1.19M
Profits Per Employee 179,967
Employee Count 7,605
Asset Turnover 0.36
Inventory Turnover 1.00

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -49.85% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -49.85%
50-Day Moving Average 118.20
200-Day Moving Average 150.43
Relative Strength Index (RSI) 57.45
Average Volume (20 Days) 30

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) 1.81

Income Statement

In the last 12 months, Biogen had revenue of EUR 9.08 billion and earned 1.37 billion in profits. Earnings per share was 9.36.

Revenue 9.08B
Gross Profit 6.87B
Operating Income 2.19B
Pretax Income 1.62B
Net Income 1.37B
EBITDA 2.85B
EBIT 2.19B
Earnings Per Share (EPS) 9.36
Full Income Statement

Balance Sheet

The company has 2.40 billion in cash and 6.13 billion in debt, giving a net cash position of -3.72 billion.

Cash & Cash Equivalents 2.40B
Total Debt 6.13B
Net Cash -3.72B
Net Cash Per Share n/a
Equity (Book Value) 15.71B
Book Value Per Share 107.23
Working Capital 2.15B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.39 billion and capital expenditures -134.06 million, giving a free cash flow of 2.25 billion.

Operating Cash Flow 2.39B
Capital Expenditures -134.06M
Free Cash Flow 2.25B
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 75.65%, with operating and profit margins of 24.16% and 15.07%.

Gross Margin 75.65%
Operating Margin 24.16%
Pretax Margin 17.85%
Profit Margin 15.07%
EBITDA Margin 31.39%
EBIT Margin 24.16%
FCF Margin 24.82%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -0.21%
Shareholder Yield -0.21%
Earnings Yield 8.35%
FCF Yield 13.75%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Biogen has an Altman Z-Score of 3.17.

Altman Z-Score 3.17
Piotroski F-Score n/a